Long acting cabotegravir for use as PrEP (Apretude®) has been added to the list of HIV therapies. Apretude® has been approved by the FDA use in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV and who have a negative HIV-1 test prior to initiation. The extended-release injectable suspension of cabotegravir can be given as few as six times per year and is initiated with a single 600 mg (3-ml) injection given one month apart for two consecutive months. After the second initiation injection, the recommended continuation injection dose is a single 600 mg (3-ml) injection given every two months.
The comedication list has also been expanded with four key COVID therapies added to the antiviral class of comedications. The new additions are:
- Molnupiravir (Lagevrio®)
- Nirmatrelvir/ritonavir (Paxlovid®)
- Sotrovimab (Xevudy®)
- Tixagevimab/cilgavimab (Evusheld®)
